StockNews.AI
LIPO
StockNews.AI
168 days

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement

1. Lipella Pharmaceuticals completes a $3.8 million private placement. 2. Funds will advance Lipella's mission for innovative therapies. 3. Spartan Capital acted as the sole placement agent. 4. The transaction reflects confidence in Lipella's clinical pipeline. 5. Details to be filed with the SEC in a Form 8-K.

5m saved
Insight
Article

FAQ

Why Bullish?

Successful fundraising improves Lipella’s financial position. Historically, similar fundraises lead to increased stock prices.

How important is it?

The fundraising indicates market confidence and supports product development, both essential for valuation.

Why Short Term?

Funds will immediately enhance operations and clinical development, likely reflecting in stock price soon.

Related Companies

SPACMDGL
March 04, 2025 13:18 ET  | Source: Spartan Capital Securities, LLC New York, NY, March 04, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the successful completion of a $3,788,000 private placement for Lipella Pharmaceuticals Inc. (Nasdaq: LIPO). Spartan Capital Securities, LLC acted as the sole placement agent in this private offering. The proceeds from this offering will further Lipella’s mission to develop innovative therapies addressing significant unmet medical needs, while also funding general corporate purposes. Jonathan Kaufman, PhD, CEO of Lipella Pharmaceuticals, remains committed to leading the company’s groundbreaking clinical pipeline and advancing transformative treatments. “We are honored to serve as the sole placement agent in this private placement for Lipella Pharmaceuticals,” said John Lowry, CEO of Spartan Capital Securities. “Lipella’s dedication to medical innovation and improving patient outcomes is commendable. This successful transaction underscores both the strength of Lipella’s vision and Spartan Capital’s commitment to facilitating impactful investment opportunities. We look forward to supporting Lipella’s continued success.” Sichenzia Ross Ference Carmel LLP served as placement agent counsel, while Sullivan & Worcester LLP acted as counsel to Lipella Pharmaceuticals Inc. Further details on the transaction will be available in the Company’s Form 8-K, to be filed with the U.S. Securities and Exchange Commission and accessible at www.sec.gov. The common shares and the common shares issuable upon the conversion of related warrants have not been registered under the Securities Act of 1933, as amended, or any state securities laws. Until registered, these securities may not be offered or sold in the United States or any state absent registration or an applicable exemption from registration requirements. This press release does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction where such offer, solicitation, or sale would be unlawful prior to registration or qualification under applicable securities laws. About Spartan Capital Securities, LLC Spartan Capital Securities, LLC is a premier full-service investment banking firm offering a comprehensive range of advisory services to institutional clients and high-net-worth individuals. Known for its expertise in capital raising, strategic advisory, and asset management, Spartan Capital delivers tailored solutions to meet clients' financial goals. For more information about Spartan Capital Securities, visit www.spartancapital.com. Contact: Spartan Capital Securities, LLC 45 Broadway, 19th Floor New York, NY 10006 investmentbanking@spartancapital.com

Related News